160 related articles for article (PubMed ID: 31874677)
1. [Lung Adenocarcinomas with Pulmonary Miliary Metastases: A Case Report and Literature Review].
Li L; Zhou L; Zhang J
Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):798-804. PubMed ID: 31874677
[TBL] [Abstract][Full Text] [Related]
2. Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations.
Kunishige M; Takeuchi E
Thorac Cancer; 2023 Dec; 14(34):3419-3420. PubMed ID: 37920971
[TBL] [Abstract][Full Text] [Related]
3. Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
Togashi Y; Masago K; Kubo T; Sakamori Y; Kim YH; Hatachi Y; Fukuhara A; Mio T; Togashi K; Mishima M
Cancer; 2011 Feb; 117(4):819-25. PubMed ID: 20886633
[TBL] [Abstract][Full Text] [Related]
4. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between EGFR, ALK Gene Mutation and Imaging
and Pathological Features in Invasive Lung Adenocarcinoma].
Yang H; Liu Z; Wang H; Chen L; Wang J; Wen W; Xu X; Zhu Q
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):147-155. PubMed ID: 35340157
[TBL] [Abstract][Full Text] [Related]
6. [Miliary cerebral carcinomatosis secondary to EGFR mutation-positive lung adenocarcinoma].
Dumoulin J; Rozensztajn N; Paradis M; Sellier J; Abel A; Giraud P; Labrune S; Chinet T
Rev Mal Respir; 2016 Jan; 33(1):67-71. PubMed ID: 25794997
[TBL] [Abstract][Full Text] [Related]
7. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
[TBL] [Abstract][Full Text] [Related]
8. Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
Okuma Y; Kashima J; Watanabe K; Homma S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1601-1611. PubMed ID: 29858682
[TBL] [Abstract][Full Text] [Related]
9. Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study.
Zhou J; Qin H; Miao J; Liu R; Wang W
Medicine (Baltimore); 2023 Jun; 102(26):e34110. PubMed ID: 37390279
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis.
Kim HJ; Kang SH; Chung HW; Lee JS; Kim SJ; Yoo KH; Lee KY
Thorac Cancer; 2015 Sep; 6(5):629-35. PubMed ID: 26445612
[TBL] [Abstract][Full Text] [Related]
12. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
13. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
15. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
[TBL] [Abstract][Full Text] [Related]
16. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
[TBL] [Abstract][Full Text] [Related]
17. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
[TBL] [Abstract][Full Text] [Related]
18. Miliary pattern on chest imaging as a presentation of EGFR-negative primary lung adenocarcinoma.
Hoffman SA; Manski S; Deepak J
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31151972
[TBL] [Abstract][Full Text] [Related]
19. Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion.
Laack E; Simon R; Regier M; Andritzky B; Tennstedt P; Habermann C; Verth CZ; Thöm I; Grob T; Sauter G; Bokemeyer C
J Thorac Oncol; 2011 Jan; 6(1):199-202. PubMed ID: 21178715
[TBL] [Abstract][Full Text] [Related]
20. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report.
Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J
Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
